1. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Issue 3 (March 2018) Authors: Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Olencki, Thomas E; Tarazi, Jamal C; Rosbrook, Brad; Fernandez, Kathrine C; Lechuga, Mariajose; Choueiri, Toni K Journal: Lancet oncology Issue: Volume 19:Issue 3(2018) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Issue 3 (4th March 2018) Authors: Jurczak, Wojciech; Ramanathan, Sundra; Giri, Pratyush; Romano, Alessandra; Mocikova, Heidi; Clancy, Jill; Lechuga, Mariajose; Casey, Michelle; Boni, Joseph; Giza, Agnieszka; Hess, Georg Journal: Leukemia & lymphoma Issue: Volume 59:Issue 3(2018) Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer. (17th July 2014) Authors: Sonpavde, Guru; Pond, Gregory R.; Armstrong, Andrew J.; Galsky, Matthew D.; Leopold, Lance; Wood, Brian A.; Wang, Shaw‐Ling; Paolini, Jolanda; Chen, Isan; Chow‐Maneval, Edna; Mooney, David J.; Lechuga, Mariajose; Smith, Matthew R.; Michaelson, M. Dror Journal: BJU international Issue: Volume 114:Number 6B(2014) Page Start: E25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗